Congruence Therapeutics announces oral presentation on CGX-195, a novel small molecule AAT corrector, at the ERS Alpha-1 Antitrypsin (AAT) Conference 2026

Summary

CGX-195 increased functional, secreted Z-A1AT and reduced polymerized Z- A1AT in cellular assays and in the PiZ mouse model MONTREAL, Oct. 23, 2026 — Congruence Therapeutics ("Congruence"), a clinical...